Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v11-EN | Version v2-FR | |
|---|---|---|
| Language | English | French |
| Date Updated | 2023-02-17 | 2022-12-16 |
| Drug Identification Number | 02371049 | 02371049 |
| Brand name | TWYNSTA | TWYNSTA |
| Common or Proper name | Twynsta 80+5mg Tablets | Twynsta 80+5mg Tablets |
| Company Name | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | BOEHRINGER INGELHEIM (CANADA) LTD LTEE |
| Ingredients | AMLODIPINE TELMISARTAN | AMLODIPINE TELMISARTAN |
| Strength(s) | 5MG 80MG | 5MG 80MG |
| Dosage form(s) | TABLET | TABLET |
| Route of administration | ORAL ORAL | ORAL ORAL |
| Packaging size | 4x7 | 4x7 |
| ATC code | C09DB | C09DB |
| ATC description | ANGIOTENSIN II ANTAGONISTS, COMBINATIONS | ANGIOTENSIN II ANTAGONISTS, COMBINATIONS |
| Reason for shortage | Demand increase for the drug. | Demand increase for the drug. |
| Anticipated start date | 2022-12-16 | 2022-12-16 |
| Actual start date | 2022-12-16 | 2022-12-16 |
| Estimated end date | 2023-02-17 | 2023-02-17 |
| Actual end date | 2023-02-16 | |
| Shortage status | Resolved | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | overselling due to generic inability to supply | |
| Health Canada comments |